HROW
Harrow, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2013-02-08
$28.54
+0.34 (+1.21%)
last quote
Want the full multi-source brief on HROW?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$28.54
High
$28.98
Low
$27.81
Previous close
$28.20
Fundamentals
Market cap
$1.07B
P/E (TTM)
—
P/S (TTM)
3.88x
P/B
34.60x
Gross margin
73.28%
Operating margin
-3.81%
Net margin
-13.51%
Rev growth (YoY)
21.05%
EPS growth (YoY)
—
ROE
-103.86%
52W high
$54.85
52W low
$26.96
Beta
0.20x
Upcoming earnings
next 30 days
2026-11-09in 4 daysafter market
Q3 2026EPS est $0.23Rev est $100.4M
Recent SEC filings
CIK 1360214filing-language history →
Recent news
2026-10-28 → 2026-11-04
SeekingAlpha · 6h
Rare Stock Picks In October 2026 - From 14 Discerning Analysts
In our monthly Rare Stock Picks series, we're highlighting October 2026 investment picks. Click here for the list of October 2026 Buy recommendations.
Yahoo · 2d
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · 2d
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio
SCOTTSDALE, Ariz., November 02, 2026--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow’s new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow’s branded ophthalmic portfoli
Yahoo · 2d
Harrow Launches HarrowRx Platform
HarrowRx to Simplify Access to Harrow Products and Integrate Into the Eyecare Practice Workflow, Providing a Single Prescribing Destination Within Existing Electronic Medical Record (EMR) SystemsNASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescrib
SeekingAlpha · 6d
Harrow's Top Two Drugs Alone Can Justify Its Current Valuation
Harrow stock trades near a 52-week low, but Vevye and Iheezo growth may drive major upside. Click for this bullish thesis on the HROW stock.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial